Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2009

01-10-2009 | Special Feature

Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer

Author: Masafumi Kurosumi

Published in: Breast Cancer | Issue 4/2009

Login to get access

Excerpt

Recently, therapeutic strategies for patients with breast cancer have made rapid advances since the introduction of molecular-targeting therapy using trastuzumab. At the same time, examination of HER-2 status using the IHC and ISH methods has become an established and accepted procedure for selection of breast cancer patients who will likely respond to trastuzumab. Recently, large-scale clinical studies have confirmed the effectiveness of anti-cancer therapies incorporating trastuzumab for metastatic as well as primary breast cancer. …
Metadata
Title
Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer
Author
Masafumi Kurosumi
Publication date
01-10-2009
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2009
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0168-y

Other articles of this Issue 4/2009

Breast Cancer 4/2009 Go to the issue

Conference Paper

Management of breast cancer: from standardization to personalization

Acknowledgment

Acknowledgment to reviewers 2009

Special Feature

Neo(adjuvant) trastuzumab treatment: current perspectives

Conference Paper

Breast cancer risk assessment for possible tailored screening for Japanese women

Conference Paper

Algorithm for in vitro diagnostic multivariate index assay

Special Feature

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits